Tomas Fait has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hormone Replacement Therapy (HRT) Shortages for Treating Menopause: What Can Clinicians Do to Relieve Symptoms and Concerns?

    by Tomas Fait, Michal Vrablik

    Hormone replacement therapy (HRT) is a treatment for acute climacteric syndrome, with the best effectivity. It also prevents bone loss and fractures. Ischemic heart disease prevention and cognitive function improvement have been observed with HRT, only when started early (critical window hypothesis). There is a large scale of complementary and alternative medicines for women in preference to non-hormonal treatment. Unfortunately, they do not always accompany reliable documentation of efficacy and safety from well-performed studies.


  • Open Access

    Feasible Influence of G-CSF on Clinical Pregnancy Outcome in Oocyte Donation Cycles for Patients with Recurrent Implantation Failure

    by Nataliya Kushniruk, Anna Stastna, Tomas Fait, Tereza Lenertova

    Background and Objectives: The aim of our single-center cohort study was the determination of the influence of the intrauterine lavage of granulocyte colony-stimulating growth factor (G-CSF) on clinical pregnancy rate in patients with a history of implantation failure older than 40 years. Materials and Methods: The study was conducted in Ferticare Prague SE between May 2018 and June 2020. Overall, 115 patients were distributed into two arms, with 48 subjects in the experimental and 67 in the control arm. All women have had a previous history of unsuccessful history of infertility treatment with their own genetic material and at least one ineffective cycle with the donated oocytes. The experimental arm underwent the intrauterine lavage of 0.5 mL of pure G-CSF from 120 to 48 h prior to embryo transfer. Results: The clinical pregnancy rate was 63.3% in the experimental arm and 47.8% in the control arm (p = 0.097 for Pearsonߣs χ2, and p = 0.133 for Fisher’s exact test). However, the mean endometrial thickness on the day of embryo transfer did not appear to be statistically different (p = 0.139). Only the difference in endometrium thickness growth was statistically significant (p = 0.023). The increase in pregnancy rate is still encouraging for the future, even if it is not significant. Conclusion: Our study suggests the trend of increased pregnancy rate after the intrauterine G-CSF lavage in the interval of 120–48 h prior to embryo transfer.


  • Usage of the levonorgestrel releasing intrauterine system in perimenopause

    by Tomáš Fait

    Levonorgestrel releasing intrauterine system have excellent contraceptive efficacy with simultaneous lowering of menstruation's blood loss. It could be used for therapy of endometrial hyperplasia in perimenopause. In position of gestagen part of the hormone replacement therapy it has high control of endometrial proliferation. It is conjoined with the zero increasing of risk of thromboembolic disease in combination with transdermal oestrogen's application.


  • Open Access

    Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study

    by Tomas Fait, Tivadar Baltazár, Leona Bubenickova, Jan Kestranek, Martin Stepan, Miroslav Muller, Pavel Turcan

    Introduction: Vaginal laxity is a widespread and undertreated medical condition associated especially with vaginal parity. Aim: To evaluate the efficacy and safety of electroporation therapy treatment of vulvovaginal laxity by the Jett Plasma for Her II device. Methods: The Jett Plasma for Her II Study is a multicentric, prospective, randomized, single-blinded, and controlled study. Women presenting with vaginal laxity were randomized to receive electroporation therapy delivered to the vaginal tissue (active—82 patients) vs. therapy with zero intensity (placebo—9 patients). Results: A total of 91 subjects whose average age was 48.69 ± 10.89 were included. Due to the results of a one-way analysis of variance, it may be concluded that in the case of the vaginal laxity questionnaire (VLQ), there is a statistically significant difference between actively treated patients and the placebo group (F1,574 = 46.91; p < 0.001). In the case of the female sexual function index (FSFI), a one-way ANOVA test also showed a statistically significant difference between the actively treated patients and the placebo group (F1,278 = 7.97; p = 0.005). In the case of the incontinence impact questionnaire-7 (IIQ-7), a one-way ANOVA test showed a statistically significant difference between the actively treated patients and the placebo group (F1,384 = 15.51; p < 0.001). It confirms that improvement of vaginal laxity is conjoined with benefits in symptoms of urinary incontinence. Biopsy performed after the end of the treatment shows an increase in the vaginal mucosa thickness by an average of 100.04% in the active group. The treatment was well tolerated with no adverse events. No topical anesthetics were required. Conclusions: Treatments of vulvovaginal laxity by electroporation therapy achieved significant and sustainable 12-month effectiveness. Responses to the questionnaires also suggest subjective improvement in self-reported sexual function, incontinence, sexual satisfaction, and urogenital distress.


  • Open Access

    Climacteric patient in office of general practitioner

    by Tomáš Fait

    Hormon?ln? substitu?n? terapie je st?le nej??inn?j?? l??bou akutn?ho klimakterick?ho syndromu i prevenc? osteopor?zy. P?i zah?jen? l??by do 10 let od menopauzy, tedy p?ed n?stupem nevratn?ch zm?n v c?vn? st?n? i nervov?ch tk?n?ch, je prevenc? ...


  • Open Access

    Does Advanced Maternal Age Comprise an Independent Risk Factor for Caesarean Section? A Population-Wide Study

    by Anna Šťastná, Tomáš Fait, Jiřina Kocourková, Eva Waldaufová

    Objective: To investigate the association between a mother’s age and the risk of caesarean section (CS) when controlling for health factors and selected sociodemographic characteristics. Methods: Binary logistic regression models for all women who gave birth in Czechia in 2018 (N = 111,749 mothers who gave birth to 113,234 children). Results: An increase in the age of a mother significantly increases the odds of a CS birth according to all of the models; depending on the model, OR: 1.62 (95% CI 1.54–1.71) to 1.84 (95% CI 1.70–1.99) for age group 35–39 and OR: 2.83 (95% CI 2.60–3.08) to 3.71 (95% CI 3.23–4.27) for age group 40+ compared to age group 25–29. This strong association between the age of a mother and the risk of CS is further reinforced for primiparas (probability of a CS: 11% for age category ≤ 19, 23% for age category 35–39, and 38% for age category 40+). However, the increasing educational attainment of young women appears to have weakened the influence of increasing maternal age on the overall share of CS births; depending on the model, OR: 0.86 (95% CI 0.80–0.91) to 0.87 (95% CI 0.83–0.91) for tertiary-educated compared to secondary-educated women. Conclusions: The age of a mother comprises an independent risk factor for a CS birth when the influence of health, socioeconomic, and demographic characteristics is considered.


  • Delayed umbilical cord clamping – benefits and risks

    by Tomáš Fait, Jan Janota

    Delayed umbilical cord clamping is a standard procedure for active management of the 3rd stage of labour. There are benefits associated with more than a 30 second delay, but 1 minute is usually recommended. For newborns, increased iron reserves are important having a positive impact on further development. A reduction in the risk of necrotizing enterocolitis and intraventricular hemorrhage is often reported in preterm births. In delayed umbilical cord clamping, no increased maternal blood loss was recorded, even in multiple pregnancies and caesarean sections.


  • Open Access

    Ageing woman at dermatology

    by Tomáš Fait

    Menopauza je spojena s poklesem produkce estrogen?. Ten m? negativn? ??inek na kvalitu i funkci k??e. Ochrann? ??inek syst?mov? pod?van?ch estrogen? je neoddiskutovateln? a prok?zan? v ?etn?ch studi?ch. Vzhledem k omezen? dob? u??v?n? syst?mov...


  • Open Access

    Evaluation of the effect of Lepidium meyenii Walpers in infertile patients: A randomized, double‐blind, placebo‐controlled trial

    by Ingrid Melnikovova, Daniela Russo, Tomas Fait, Michaela Kolarova, Jan Tauchen, Nataliya Kushniruk, Roberto Falabella, Luigi Milella, Eloy Fernández Cusimamani

    Male infertility refers to the inability to conceive a natural pregnancy in a fertile female, and approximately 15% of reproductive‐aged couples worldwide face this problem. Several plants were used to treat fertility disorders and, among them, Lepidium meyenii, a folk medicament of Andean regions, is still used to enhance vitality and treat sterility in humans and domestic animals. The aim of the study was to evaluate the effects of L. meyenii Walpers on infertile patients by a randomized, double‐blind, placebo‐controlled trial. Fifty patients suffering from various reproductive‐related problems were enrolled for 16 weeks to evaluate the effect of yellow maca on semen quality and serum hormone levels. Treatment with maca improved the percentage of sperm concentration by 40%, whereas the placebo improved by 76% after 8 and 16 weeks of treatment, but the results were statistically non‐significant. No statistically significant change in hormone levels was reported by using maca, except a decrease in the level of free testosterone. Results are not sufficient to assess the efficacy of maca on male fertility. Further investigation and trials are required to obtain conclusive results.


  • Open Access

    Menopause hormone therapy: latest developments and clinical practice

    by Tomas Fait

    Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.